Weight-Loss Plateau during Lifestyle Intervention Predicts Treatment Response in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease and Obesity
Obesity Facts · 2025
DOI: 10.1159/000543818 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Obesity Facts, 2025. Verfasst von Ling Luo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Weight Loss, Obesity, Fatty Liver. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Whether the weight-loss plateau and its values differ in obesity with or without metabolic dysfunction-associated steatotic liver disease (MASLD) undergoing continuous lifestyle intervention remains unknown. We aimed to investigate this problem.
Methods
This prospective observational cohort study included 305 patients with obesity and MASLD and 103 matched individuals with non-MASLD from January 2015 to April 2023, with a 12-month follow-up to monitor weight changes. Liver biochemistry, liver fat content with magnetic resonance imaging-based proton density fat fraction with Dixon sequence, and liver stiffness measurement via 2D-SWE were assessed at baseline and after 12 months. A validated weight trajectory regression model was applied to estimate the weight-loss plateau.
Results
Individuals with MASLD and non-MASLD presented a similar timing of the weight plateau at 6 months, but patients with MASLD experienced less weight loss and maintained their weight plateaus longer compared to those with non-MASLD. Among patients with MASLD, a greater total weight loss (TWL) at 6 months was associated with better treatment response in hepatic steatosis and injury (all p < 0.001). Further multivariate logistic analysis showed that the 6-month TWL was an independent predictor of subsequent improvements in hepatic steatosis (OR: 0.78, 95% CI: 0.72–0.84) and alanine aminotransferase levels (OR: 0.82, 95% CI: 0.76–0.90) at 12 months.
Conclusion
Patients with MASLD experienced gradual weight loss followed by a prolonged plateau, with the maximum reduction observed at 6 months. The degree of 6-month weight loss was a valuable prognostic factor for the 12-month hepatic treatment outcomes. Strategies to overcome this plateau are essential for improving long-term treatment efficacy in MASLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Gastrointestinal Endoscopy Center, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
- Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Department of Ultrasound, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Department of Nutrition, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Zitieren
APA
Luo, L., Ye, J., Zhou, T., Dong, Z., Feng, S., Wang, W., Zhuo, S., & Zhong, B. (2025). Weight-Loss Plateau during Lifestyle Intervention Predicts Treatment Response in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease and Obesity. Obesity Facts. https://doi.org/10.1159/000543818
Vancouver
Luo L, Ye J, Zhou T, Dong Z, Feng S, Wang W, et al. Weight-Loss Plateau during Lifestyle Intervention Predicts Treatment Response in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease and Obesity. Obesity Facts. 2025. doi:10.1159/000543818
BibTeX
@article{Luo2025,
author = {Luo, Ling and Ye, Junzhao and Zhou, Ting and Dong, Zhi and Feng, Shiting and Wang, Wei and Zhuo, Shuyu and Zhong, Bihui},
title = {Weight-Loss Plateau during Lifestyle Intervention Predicts Treatment Response in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease and Obesity},
journal = {Obesity Facts},
year = {2025},
doi = {10.1159/000543818}
}
EUVIMED